All News

CURE® surveyed its audience to gather insight into what unexpected lessons cancer has taught them. Here’s what they had to say.

It’s easy to question treatment choices patients with cancer make, but my job as the mother of a patient was to be supportive.

In 2018, 18 trekkers completed an awe-inspiring hike of the Himalayan highlands to the doorstep of the world’s tallest mountain, Mount Everest, to raise awareness and funding for multiple myeloma, a type of blood cancer. Three of the climbers discuss a bond that hasn’t broken.

I went from being an avid runner to running from information about my lung cancer. But now I embrace my diagnosis and am an active participant in my care.

I didn’t let my cancer diagnoses get in the way of living life.

An oncology nurse and cancer survivor inspired another person with lung cancer to “continue the fight to live.”

Dr. Estelamari Rodriguez serves patients with lung cancer in more than just a clinical capacity, her Lung Cancer Hero® nominator wrote.

I turned my cancer-related depression and frustration with the health care system into something positive for others with the disease.

Walking has played a key role in my cancer experience, as it helps my mental and physical health.

Talzenna Plus Xtandi lengthened time to progression in men with metastatic castration-resistant prostate cancer.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Dr. Daniel P. Petrylak about survivorship in prostate cancer.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Dr. Daniel P. Petrylak about the long-term effects associated with a prostate cancer diagnosis.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Dr. Daniel P. Petrylak about PSMA, what it is and how it is advancing the prostate cancer landscape.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Tony Crispino about the importance of patient-physician communication in prostate cancer.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Tony Crispino about seeking support after a prostate cancer diagnosis.

The use of a multi-agent chemotherapy regimen resulted in improved outcomes in a group of children with pleuropulmonary blastoma, a rare form of lung cancer, when compared with other regimens.

The truth is I stagger back and forth between the two camps — tell it like it is or walking on sunshine. It depends on the day, my treatment regimen, the lab or scan results, the losses and the gains.

A patient with metastatic breast cancer shares how she learned that her disease was recently reclassified as HER-2 low, and what it was like to first learn about the FDA-approved drug years before she would be prescribed the treatment.

High levels of inflammation, as well as high BMI and later-stage disease, may be predictors of weakness after chemotherapy treatment in older patients with breast cancer, which may hold potential in guiding treatment decisions.

Combination treatment with two PD-1 inhibitors — Yervoy and Opdivo — did not improve survival without cancer recurrence compared with Opdivo alone in patients with high-risk melanoma, a type of skin cancer.

A breast cancer research nurse and lung cancer survivor stresses the importance of participating in clinical trials that are investigating the latest treatments.

The switch from private insurance to Medicare was a struggle — especially considering my need for cancer care — that was not solved by numerous phone calls, but by Twitter instead.

Nearly two thirds of patients with GISTs — a rare type of cancer that often begins in the digestive system — indicated that their overall quality of life after treatment had been affected by cancer-related cognitive impairments, also referred to as “chemo brain,” according to analysis of survey data.

Looking back on my breast cancer experience, I contemplate what it means to thrive.

CURE® surveyed its audience to see how cancer-related pain or treatment-related side effects interfered with their ability to be independent. Here’s what they had to say.

Treatment with an investigational drug elicited a median progression-free survival (time from treatment until disease progression or death) of 8.9 months among patients with a form of unresectable or metastatic squamous non-small cell lung cancer, according to trial findings.

Of course, I want the best cancer care, but I realized that the beauty of the environment where I get it is important too.

Men with metastatic castration-resistant prostate cancer lived longer without their disease progressing when treated with Rubraca compared to standard of care.